

Opinion

# Precision and personalized vaccines needed to face COVID-19 pandemic

Dahmani Fathallah M\*

Department of Life Sciences, Health Biotechnology, College of Graduate Studies, Arabian Gulf University, Manama, Bahrain

Among the abounding lessons we learned from the SARS-CoV-2 pandemic is the uttermost determinant that people are not equal before the severity of COVID-19. Indeed, the disease course differs with age, gender, ethnicity, underlying clinical conditions and virus variants. Other diseases modifying factors are associated with genetic traits such as those driving the immune response, the blood groups, the coagulation system and the ACE2 receptor variants [1-4].

Currently, nine different vaccines are being used to face the plethora of biological variety associated with COVID-19. Having been tested using conventional clinical trials focusing mainly on safety and efficacy, these vaccines showed variable efficacy levels and none confers sterilizing immunity. In addition, the efficacy of almost all COVID-19 vaccines is challenged by the emergence of novel viral variants and mitigation efforts have to be pursued post vaccination. Furthermore, some instances of concerning undesirable effects such as thrombocytopenia and micro blood clots is halting the full deployment of at least two vaccines. With no scientific consensus about the availability of a drug for the efficient treatment of COVID-19 particularly the severe forms, vaccination remains the best hope to get out of the pandemic. However, the above issues have introduced a debate on which vaccine to take and some legitimate questions arose:

Could variations in vaccines performance and undesirable effects be associated to the disease modifying factors aforementioned? Is it optimal to deal with a new pandemic frontier by deploying vaccines tested using the conventional way? Can anti-SARS-CoV-2 vaccine(s) allow life to go back to pre-pandemic status?

The answer to these questions would come from conducting multiple clinical trials in defined settings such as clinically and genetically defined groups. We could learn which vaccine would be more adapted to each age group or to people with underlying comorbidities such as obesity, heart disease, or those with a given HLA type, blood groups or a common ACE2 variant.

In addition, development of precision vaccines and personalization of vaccination would probably be a winning

More Information

\*Address for Correspondence:

Dahmani Fathallah M, Professor, Department of Life Sciences, Health Biotechnology, College of Graduate Studies, Arabian Gulf University, PO Box. Manama 22971, Bahrain, Tel: +973 34606602/+973 17239602; Email: d.fathallah@agu.edu.bh

Submitted: April 21, 2021


Approved: April 27, 2021

Published: April 28, 2021

**How to cite this article:** Dahmani Fathallah M. Precision and personalized vaccines needed to face COVID-19 pandemic. *Insights Clin Cell Immunol.* 2021; 5: 003-003.

DOI: 10.29328/journal.icci.1001017

**Copyright:** © 2021 Dahmani Fathallah M. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



strategy to fight the spread of SARS-Cov-2 and help control the pandemic. A precision vaccine for SARS-CoV-2 would be a vaccine that target the genetic changes accumulated by the virus. Personalized RNA-based cancer vaccines are showing spectacular success particularly in treating melanoma [5]. Therefore, RNA vaccine technology that is already used in two of the currently deployed COVID-19 vaccines could be a gateway for introducing precision and personalized vaccination against SARS-CoV-2. However, organizational and economic aspects might limit and/or delay the globalization of precision and personalized anti-SARS-CoV-2 vaccination.

## References

1. Fergusson NA, Mitra AR, Griesdale DEG, Devine DV, Stukas S, et al. The association of ABO blood group with indices of disease severity and multiorgan dysfunction in COVID-19. *Blood Adv.* 2020; 4: 4981-4989. [PubMed: https://pubmed.ncbi.nlm.nih.gov/33057633/](https://pubmed.ncbi.nlm.nih.gov/33057633/)
2. Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, et al. Human Leukocyte Antigen Susceptibility Map for Severe Acute B.R. Respiratory Syndrome Coronavirus 2. *J Virol.* 2020; 94: e00510-20. [PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307149/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307149/)
3. Spencer-Gold M, Sehayek D, Gabrielli S, Zhang X, McCusker C, et al. COVID-19 and comorbidities: a systematic review and meta-analysis. *Postgraduate Med.* 2020; 132:8, 749-755. [PubMed: https://pubmed.ncbi.nlm.nih.gov/32573311/](https://pubmed.ncbi.nlm.nih.gov/32573311/)
4. Ashoor D, Ben Khalaf N, Marzouq M, Al Jarjanazi H, Chlif S, et al. A computational approach to evaluate the combined effect of SARS-CoV-2 RBD mutations and ACE2 receptor genetic variants on infectivity: The COVID-19 host-pathogen nexus. *bioRxiv/PMC.* 2021.
5. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, et al. An Immunogenic Personal Neoantigen Vaccine for Melanoma Patients. *Nature.* 2017; 547: 217-221.